Compare TRIB & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | QNRX |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 9.2M |
| IPO Year | 1996 | 2023 |
| Metric | TRIB | QNRX |
|---|---|---|
| Price | $6.79 | $4.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $20.38 |
| AVG Volume (30 Days) | 13.2K | ★ 31.6K |
| Earning Date | 06-16-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.89 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $3.25 |
| 52 Week High | $14.17 | $23.50 |
| Indicator | TRIB | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 36.58 |
| Support Level | $6.85 | $4.03 |
| Resistance Level | $7.45 | $5.18 |
| Average True Range (ATR) | 0.88 | 0.30 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 30.19 | 19.58 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.